Management

Ted Raad
Ted RaadTed Raad

Ted Raad
Chief Executive Officer

Mr. Raad was appointed Chief Executive Officer in 2019. Prior to his appointment, he served as PULMATRiX’s Chief Business Officer and led commercial and business development efforts. He has 20 years of commercial healthcare and life science ...see more leadership experience and most recently served as Chief Commercial Officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation’s largest independent home infusion provider. Prior to that, he was a business unit head at Sunovion with overall responsibility for CNS and respiratory products, including assets in asthma and COPD. During his time at Sunovion, Mr. Raad led multiple products through clinical development to commercialization and implemented new strategic alliances in the US and Japan. Earlier in his career, he also gained direct launch experience with Sporanox®, Janssen’s oral itraconazole product to treat fungal infections, and brings that experience to the PULMATRiX PUR1900 program. Mr. Raad holds a BS in Business Administration from University of Colorado at Boulder and an MBA from Thunderbird Global School of Global Management. ...see less

Michelle Siegert
Michelle SiegertMichelle Siegert

Michelle Siegert
Vice President of Finance

Ms. Siegert is responsible for the corporate finance function and is the principal finance and accounting officer for PULMATRiX. Since Ms. Siegert joined the company in 2010, she has progressed through numerous roles of increasing responsibility. ...see more She began her finance career at W.R. Grace & Co. and has completed more than 25 years of financial, transactional, and operational experience in both private and public companies. Ms. Siegert holds a Bachelor of Arts degree in Management with a concentration in Accounting from Simmons University. ...see less

Rusty Clayton
Rusty ClaytonRusty Clayton

Rusty Clayton
Medical Director

Dr. Clayton leverages over 15 years of executive experience in pharmaceutical, biologics, and medical device development and commercialization as a consultant in clinical development, medical affairs, and regulatory affairs. Prior to becoming a consultant, Dr. Clayton was the ...see more chief medical officer at Alcresta Therapeutics, a medical device company. While at Alcresta, Dr. Clayton led clinical development and medical affairs, overseeing the design and execution of pivotal clinical studies as well as developing a medical affairs capability in support of a new product launch. Prior to Alcresta Therapeutics, Dr. Clayton was the senior vice president of research and development at Discovery Labs, a pharmaceutical and medical device company, where he led the scientific and regulatory efforts leading to the marketing authorization of Discovery’s first product. Dr. Clayton is a board certified pediatric pulmonologist who practiced at St. Christopher’s Hospital for Children and the Children’s Hospital of Philadelphia prior to beginning his career in the pharmaceutical, biologics, and medical device industry. Dr. Clayton graduated from the Philadelphia College of Osteopathic Medicine. ...see less

Michael Lipp, PhD
Michael Lipp, PhDMichael Lipp, PhD

Michael Lipp, PhD
Strategic Advisor

Mr. Lipp is currently the Senior Vice President of Pharmaceutical Development at Nocion Therapeutics Inc., a biotech startup focusing on the development of novel drug candidates (“Nocions”) for the treatment of various conditions related to pain and itch. He has over two ...see more decades of experience in pharmaceutical development and drug delivery technologies ranging from the preclinical stage through commercial approval. Prior to joining Nocion, Mr. Lipp was head of Pharmaceutical Development at Civitas Therapeutics through its acquisition by Acorda Therapeutics. At Acorda, Mr. Lipp was Site Head of the Acorda Waltham R&D Facility and led the efforts related to the Chemistry, Manufacturing and Control (CMC) activities associated with Inbrija™ which was approved by the FDA in 2018 as the first in-class treatment for OFF episodes in Parkinson’s Disease.

Mr. Lipp was previously the Vice President of Pharmaceutical Development and Intellectual Property at PULMATRiX where he was a co-inventor of the iSPERSE™ technology. Prior to PULMATRiX, Mr. Lipp was Director of Formulation Development at Alkermes, managing and directing formulation and pharmaceutical development activities related to pulmonary, injectable, and oral platforms. Mr. Lipp began his career as a Post-Doctoral Fellow working with Advanced Inhalation Research (AIR®), where he became a Staff Scientist focusing on pulmonary product development prior to its acquisition by Alkermes.

Mr. Lipp received his B.Sc. in Chemical Engineering from Cornell University and his Ph.D. in Chemical Engineering and Materials Science from the University of California, Santa Barbara. Mr. Lipp pursued a NIH Postdoctoral Fellowship at the Massachusetts Institute of Technology in the laboratory of Professor Robert S. Langer (one of the Founders of AIR), where he remains a Research Affiliate.
...see less